Biocryst Pharmaceuticals Inc BCRX
Biocryst Pharmaceuticals Inc (Nasdaq: BCRX) is an immunology/inflammation drug developer. Its lead program, ORLADEYO (berotralstat), is in Phase 3 for prevention of hereditary angioedema (HAE) attacks.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ORLADEYO (berotralstat) capsule and pediatric oral pellets | HAE prophylaxis | small molecule | Approved |
| RAPIVAB (peramivir) | acute uncomplicated influenza | small molecule | Approved |
| navenibart (STAR-0215) | HAE prophylaxis | antibody | Phase 3 |
| BCX17725 | Netherton syndrome | protein/peptide | Phase 1 |
| avoralstat | diabetic macular edema | small molecule | Phase 1 |
| STAR-0310 | atopic dermatitis | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.